Recombinant Human IGF-BP4, Insect Cell (Recombinant Human Insulin-like Growth Factor-Binding Protein 4, Insect Cells Derived; rHuIGF-BP4, Insect Cell);重组人胰岛素样生长因子结合蛋白4,昆虫细胞衍生
Synonyms
BP-4; IBP4; IGFBP-4; HT29-IGFBP
Purity
>97% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 cells is less than 0.1µg/ml, corresponding to a specific activity of >1.0×10^4IU/mg in the presence of 14ng/ml of rHuIGF-II.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2µM filtered concentrated solution in 20mM Tris-HCl, pH8.0, 150mM NaCl.
Endotoxin
Less than 0.1EU/µg of rHuIGF-BP4, Insect Cell as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
IGFBP-4 (insulin-like growth factor binding protein 4) is member of the IGFBP family of structurally similar secreted glycoproteins that maintain IGF-I and IGF-II in the circulation and direct them to their target tissues. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. IGFBP-4 consistently inhibits several cancer cells in vivo and in vitro.